Abstract
We have previously reported the results of two multicenter European studies, investigating the efficacy and toxicity of continuous infusion Interleukin-2 (IL-2) alone (1) and IL-2 with LAK cells (2). The therapeutic outcome of these studies was in accordance with the results published in the world literature (3). This means that the response rates were between 15 and 25% and that the overall median survival of 8 months did not appear different from that observed in non-selected historical and IL-2 treated controls (4).
Keywords
- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Perpendicular Diameter
- Induction Cycle
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
Von der Maase H, Geertsen P, Thatcher N, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma-a European multicenter phase II study. Eura J Cancer 27: 1583–1589, 1991.
Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer Clin Oncol 25: 21–28, 1989.
Osterwalder B. Clinical studies with interleukin-2: an overview. In: Veronesi U, ed. Lymphohaematopoietic growth factors in cancer therapy II. Berlin Springer-Verlag 1992: 57–86.
Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475–480, 1992.
Cameron R, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810–5817, 1988.
Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874, 1989.
Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2a in cancer patients: A phase I study. J Clin Oncol 7: 1726–1732, 1989.
WHO handbook for reporting results of cancer treatment Geneva 1979.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Ass 53: 457–481, 1958.
Kruit WHJ, Bolhuis RLH, Goey SH, et al. Interleukin-2 induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 11: 000–000, 1993.
Budd GT, Osgood B, Barna B, et al. Phase I clinical trial of interleukin-2 and a-interferon: Toxicity and immunologic effects. Cancer Res 49: 6432–6436, 1989.
Hirsch M, Lipton A, Harvey H, et al. Phase I study of interleukin-2 and interferona2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8: 1657–1663, 1990.
Bukowski RM, Murthy S, Sergi J, et al. Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-a2a: Clinical effects. J Biol Response Mod 9: 538–545, 1990.
Sznol M, Mier JW, Sparano J, et al. A phase I study of high-dose interleukin-2 in combination with interferon-2b. J Biol Response Mod 9: 529–537, 1990.
Rosenberg SA. Adoptive cellular therapy in patients with advanced cancer; An update. Biol Ther Cancer 1: 1–15, 1991.
Atzpodien J, Allhoff E, Korfer A, et al. Treatment strategies in patients with metastatic renal carcinoma. Onkologie 15 (s): 24, 1992.
Ilson DH, Motzer RJ, Kradin RL, et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10: 1124–1130, 1992.
Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10: 414–421, 1992.
Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 10: 804–809, 1992.
Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group trial. Mol Biother 4: 4–9, 1992.
Thomas H, Barton C, Saini A, Dalgleish A, Waxman J. Sequential interleukin2 and alpha interferon for renal cell carcinoma and melanoma. Eur J Cancer 28: 1047–1049, 1992.
Lipton A, Harvey H, Givant E, et al. Interleukin-2 and interferon a-2a outpatient therapy for metastatic renal cell carcinoma. J Immunoth 13: 122–129, 1993.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag New York Inc.
About this paper
Cite this paper
Stoter, G. et al. (1995). Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer. In: Biology of Renal Cell Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2536-2_20
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2536-2_20
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7571-8
Online ISBN: 978-1-4612-2536-2
eBook Packages: Springer Book Archive